Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor screening kit based on blood analysis

A technology for tumor screening and blood analysis, applied in the direction of material excitation analysis, fluorescence/phosphorescence, etc., can solve the problems of difficult observation and missed detection, and achieve the effect of avoiding missed detection and high enrichment efficiency

Pending Publication Date: 2022-07-12
上海翊嘉生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Aiming at the deficiencies of the prior art, the present invention provides a tumor screening kit based on blood analysis, which solves the problems of missed detection and difficult observation in the existing detection technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The embodiment of the present invention provides a tumor screening kit based on blood analysis, the kit includes: a dye enhancement solution for enhancing the dyeing effect and a specific antibody with a fluorescent dye label.

[0028] Specific antibodies include: CD19 antibody, CD3 antibody, antibody targeting CD20, and SIRPα antibody.

[0029] The dyeing enhancement solution includes raw materials in the following percentages: 1% to 5% of surfactant, 90% to 94% of biological buffer, and 0.5% to 0.8% of polyethylene glycol.

[0030] The biological buffer is a phosphate buffer, wherein the phosphate buffer includes raw materials of 40%-45% sodium dihydrogen phosphate and 40%-45% disodium hydrogen phosphate by percentage mass.

[0031] The surfactant is an anionic polyacrylamide.

[0032] The kit also includes fluorescent spot-labeled fluorescent probes.

[0033] The kit also includes a lymphocyte separation solution and a leukocyte dilution solution, and the lymphocyt...

Embodiment 2

[0042] The embodiment of the present invention provides a tumor screening kit based on blood analysis, the kit includes: a dye enhancement solution for enhancing the dyeing effect and a specific antibody with a fluorescent dye label.

[0043] Specific antibodies include: CD19 antibody, CD3 antibody and SIRPα antibody.

[0044] The dyeing enhancement solution includes raw materials in the following percentages: 5% to 10% of surfactant, 80% to 84% of biological buffer, and 0.5% to 0.8% of polyethylene glycol.

[0045] The biological buffer is a phosphate buffer, wherein the phosphate buffer includes raw materials of 30%-35% sodium dihydrogen phosphate and 50%-65% disodium hydrogen phosphate by percentage mass.

[0046] The surfactant is an anionic polyacrylamide.

[0047] The kit also includes fluorescent spot-labeled fluorescent probes.

[0048] The kit also includes lymphocyte separation liquid and leukocyte dilution liquid, and the lymphocyte separation liquid includes raw ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a tumor screening kit based on blood analysis, and relates to the technical field of blood detection. The tumor screening kit based on blood analysis comprises a staining enhancement solution for enhancing the staining effect and a specific antibody with a fluorescent staining mark, and the staining enhancement solution is prepared from the following raw materials in percentage by mass: 1%-5% of a surfactant, 90%-94% of a biological buffer solution and 0.5%-0.8% of polyethylene glycol. The leukocyte and the residual erythrocyte can be removed at one time, the enrichment efficiency is higher, interference of other cells on fluorescent staining can be eliminated after enrichment treatment, better observation through a fluorescence microscope is facilitated, expression on the surfaces of most acute myelogenous leukemia cells is achieved, and the application prospect is wide. The targeted CD20 antibody is a bispecific antibody taking a red blood cell surface antigen CD3 and a white blood cell surface antigen CD20 as targets, adapts to the heterogeneity of cells, and avoids the condition of leak detection.

Description

technical field [0001] The invention relates to the technical field of blood detection, in particular to a tumor screening kit based on blood analysis. Background technique [0002] Tumor screening is an important way to detect cancer and precancerous lesions at an early stage. Various blood test indicators in physical examination, B-ultrasound, X-ray, digital anorectal examination, Pap smear and mammography in gynecological physical examination are all commonly used methods for screening tumors. It is an important means of early detection of cancer, and it can detect and identify various malignant tumors by detecting whether various tumor markers in the blood are elevated. Such as: alpha-fetoprotein AFP can check primary hepatocellular carcinoma, gonadal embryonal tumor. When the carcinoembryonic antigen CEA is significantly elevated, colon cancer, gastric cancer, lung cancer, and bile duct cancer are common; it is also elevated in the presence of liver cancer, breast can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N21/64
CPCG01N21/6428G01N21/6458G01N2021/6439
Inventor 皇亚楠陈立伟
Owner 上海翊嘉生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com